<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of locally advanced cervical cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of locally advanced cervical cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of locally advanced cervical cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Michael Straughn, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catheryn Yashar, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arno J Mundt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Women with locally advanced cervical cancer (stage IB3 to IVA) have a higher rate of recurrence and worse survival than those with early-stage disease (stage IA to IB2). After surgery alone, the rate of relapse is at least 30 percent, and five-year survival rates range from 80 percent for stage IB disease to 30 percent for stage III disease [<a href="#rid1">1,2</a>].</p><p>The approach to women with locally advanced cervical cancer is reviewed here. Because the predominant histology of cervical cancer is squamous cell carcinoma, specific issues related to other histologies and other topics relevant to cervical cancer in general are covered elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13930.html" rel="external">"Small cell neuroendocrine carcinoma of the cervix"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13929.html" rel="external">"Invasive cervical adenocarcinoma"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION OF LOCALLY ADVANCED-STAGE CERVICAL CANCER</span><span class="headingEndMark"> — </span>Following staging, locally advanced cervical cancer is defined by the presence of any of the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Confined to the cervix with a clinically visible tumor &gt;4 cm in greatest dimension (stage IB3)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Invades beyond the uterus but not to the pelvic wall or to the lower third of vagina (stage II)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extends to the pelvic sidewall, and/or involves the lower third of vagina, and/or causes hydronephrosis or a nonfunctioning kidney, and/or involves pelvic and/or para-aortic lymph nodes (stage III)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Invades the mucosa of the bladder or rectum, or extends beyond the true pelvis (stage IVA)</p><p></p><p>The International Federation of Gynecology and Obstetrics (FIGO) staging system is listed in the table  (<a class="graphic graphic_table graphicRef119447" href="/d/graphic/119447.html" rel="external">table 1</a>). The American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging system is shown in the table  (<a class="graphic graphic_table graphicRef139268" href="/d/graphic/139268.html" rel="external">table 2</a>) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes"</a>.)</p><p class="headingAnchor" id="H20013012"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>All women with cervical cancer should undergo a lymph node evaluation, which impacts stage and treatment [<a href="#rid3">3-5</a>]. For women with locally advanced disease (stages IB3 to IVA) for whom primary chemoradiation is planned, we obtain a positron emission tomography (PET)/computed tomography (CT) scan prior to treatment to evaluate the extent of disease, with particular attention to lymph node metastases to provide information to design radiation fields. (See  <a class="medical medical_review" href="/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes"</a>.)</p><p>For women with suspected para-aortic node involvement based on CT scan, some experts proceed with a lymphadenectomy or a CT-guided biopsy for pathologic confirmation of nodal status. At other centers, F-18 fluorodeoxyglucose (FDG) uptake in the para-aortic nodes is sufficient evidence of nodal involvement, and further work-up is not performed. Regardless of whether pathologic confirmation is obtained, treatment is required if para-aortic node involvement is detected. (See  <a class="medical medical_review" href="/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes", section on 'Surgical evaluation of lymph nodes'</a> and <a class="local">'Treatment of para-aortic nodes'</a> below.)</p><p>Patients with renal insufficiency should undergo imaging to determine whether the etiology is urinary tract obstruction (which is diagnostic of stage III disease) or intrinsic renal disease. Some experts obtain upper urinary tract imaging for all patients with more than a microscopic tumor. In our practice, we obtain non-contrast CT or magnetic resonance imaging if a woman presents with an elevated serum creatinine.</p><p>Any urinary tract obstruction should be corrected prior to cancer treatment, especially in patients who are otherwise candidates for primary chemoradiation. In a retrospective study performed by the Gynecologic Oncology Group involving 539 women with stage III cervical cancer (44 percent of whom presented with hydronephrosis) treated with chemoradiation, women who received treatment for ureteral obstruction had a significantly longer progression-free survival (PFS) and median overall survival (OS) than those in whom obstruction was not treated (PFS: median, 18 versus 10 months; OS: median, 34 versus 17 months) [<a href="#rid6">6</a>]. A discussion on the etiology of ureteral obstruction and its management is covered separately. (See  <a class="medical medical_review" href="/d/html/15182.html" rel="external">"Placement and management of indwelling ureteral stents"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PRIMARY CHEMORADIATION</span><span class="headingEndMark"> — </span>For women with locally advanced cervical cancer, we administer primary chemoradiation [<a href="#rid7">7</a>], although we acknowledge that the benefits of treatment are greater with earlier (stage IB to IIB) versus more advanced stage (stage III to IVA).</p><p>We do not proceed with primary surgery in women with advanced cervical cancer because surgery is not likely to be curative and these patients usually require adjuvant treatment, which is associated with a high incidence of morbidity [<a href="#rid8">8-10</a>]. In a 2010 study of patients with stage IIB disease treated with primary surgery plus postoperative radiation therapy (RT, n = 34) or primary chemoradiation (n = 25), the rate of serious (grade 3/4) complications was doubled among those treated with primary surgery/RT (26 versus 12 percent) [<a href="#rid9">9</a>].</p><p>A 2010 meta-analysis of randomized controlled trials suggested benefit of chemoradiation for women with locally advanced cervical cancer relative to RT alone, although more definitive data are still needed [<a href="#rid11">11</a>]. In this meta-analysis, compared with primary RT, the use of chemoradiation resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>A reduction in the risk of death (hazard ratio [HR] 0.81, 95% CI 0.71-0.91), which translated into a 6 percent absolute improvement in survival at five years. There was a greater benefit for chemoradiation over radiation in the two trials that gave chemoradiation plus adjuvant chemotherapy (HR 0.46, 95% CI 0.32 to 0.66), which translated into an absolute survival benefit of 19 percent at five years. However, these two trials were relatively small, and had differing designs and limited follow-up. Thus, further data are needed.</p><p></p><p>In the meta-analysis, additional findings associated with chemoradiation versus RT alone included:</p><p class="bulletIndent1"><span class="glyph">●</span>A reduction in the risk of recurrence (HR 0.78, 95% CI 0.70-0.87), which translated into an 8 percent absolute improvement in progression-free survival (PFS) at five years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Statistically significant absolute benefits of chemoradiation versus radiation on five-year locoregional disease-free survival (DFS; 9 percent) and metastases‐free survival (7 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher rates of serious hematologic and gastrointestinal toxicity in trials using platinum-based chemoradiation, but not in trials using non-platinum-based regimens.</p><p></p><p>Subsequent trials specifically in patients with stage IIIB disease have found both DFS and overall survival (OS) benefits with chemoradiation versus RT alone [<a href="#rid12">12,13</a>].</p><p class="headingAnchor" id="H24941777"><span class="h2">Chemotherapy regimen</span><span class="headingEndMark"> — </span>Chemotherapy is usually administered with either single-agent <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or the combination of cisplatin plus <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) for the treatment of cervical cancer. Of these, we recommend weekly cisplatin (40 mg/m<sup>2</sup>) during RT [<a href="#rid11">11,14,15</a>]. Single-agent cisplatin administered with RT achieves similar outcomes to cisplatin plus FU and has a better toxicity profile. This was demonstrated in a randomized trial of 155 women with stage IIB to IVA cervical cancer (without para-aortic node involvement) who were randomly assigned treatment with RT plus either cisplatin or cisplatin plus FU [<a href="#rid14">14</a>]. At a median follow-up of 39 months, compared with cisplatin plus FU, treatment with cisplatin resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>A higher rate of completion of chemoradiation (71 versus 60 percent, respectively)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less serious (grade 3/4) hematologic toxicity (26 versus 43 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar complete response rate (91 percent in both arms) and OS rate at four years (67 and 70 percent)</p><p></p><p>Whether <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> in combination with an alternative agent to FU would improve survival outcomes is not clear. A phase III trial that enrolled 515 women compared cisplatin alone with cisplatin plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> during concurrent RT [<a href="#rid16">16</a>]. Women randomized to combination chemotherapy also received two additional 21-day cycles of cisplatin plus gemcitabine after completion of RT. With a median follow-up of three years, the use of cisplatin plus gemcitabine resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>An improvement in PFS compared with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> alone (HR for progression 0.68, 95% CI 0.49-0.95; three-year PFS 74 versus 65 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An improvement in OS (HR for death 0.68, 95% CI 0.49-0.95)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>But was associated with significantly more serious (grade 3/4) toxicities (87 versus 46 percent) and rate of hospitalizations (30 versus 11)</p><p></p><p>It is not clear whether the benefits of the investigational treatment were due to the use of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> during RT or following chemoradiation. Therefore, we continue to prescribe cisplatin alone during chemoradiation. (See <a class="local">'No role for systemic chemotherapy after chemoradiation'</a> below.)</p><p class="headingAnchor" id="H100866196"><span class="h3">Patients with potential contraindications to cisplatin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a> is associated with significant toxicities, including risks of long-standing neuropathy and potentially chronic renal insufficiency, and patients with chronic or persistent comorbidities (eg, patients with chronic renal failure or severe baseline neuropathy) face a greater risk of experiencing these complications. We prefer to treat these patients with weekly <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> dosed at area under the curve (AUC) 2 rather than exposing patients to the nephrotoxic effects of cisplatin. However, decisions regarding the choice of agent to administer with RT should be based on patient and provider preferences.</p><p>It is important to note that patients who present with acute organ dysfunction secondary to locally advanced cervical cancer should be worked up for a potentially correctable etiology. For patients with advanced cervical cancer, this most often presents as acute renal failure due to tumor-related hydronephrosis. These patients may experience a normalization of renal function following a ureteral stent or nephrostomy tube placement. Following normalization of renal function, these patients should receive primary chemoradiation with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>. (See <a class="local">'Primary chemoradiation'</a> above.)</p><p>Options for treatment of locally advanced cervical cancer in patients at risk for serious cisplatin-related toxicities are discussed below.</p><p class="headingAnchor" id="H2483633"><span class="h4">Carboplatin</span><span class="headingEndMark"> — </span>Based on preclinical data showing that <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> is an effective radiosensitizer [<a href="#rid17">17</a>], it is sometimes used in lieu of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> in these patients. However, the data on single-agent carboplatin are limited [<a href="#rid18">18-21</a>].</p><p>As an example, in one prospective study, 51 patients with predominantly advanced disease (stage IIB or higher) were treated with <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> (100 mg/m<sup>2</sup>) concurrently with RT [<a href="#rid21">21</a>]. Their outcomes were compared with historical controls comprised of 48 women treated with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus RT. Treatment with carboplatin plus RT resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>A similar overall response rate compared with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus RT (90 versus 88 percent, respectively; p = 0.31).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No difference in survival outcomes at three years. The PFS rate was 78 and 80 percent, respectively (HR 1.21, 95% CI 0.52-2.81); the OS rate was 88 and 94 percent (HR 1.80, 95% CI 0.49-6.54).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No difference in the incidence of serious (grade 3/4) toxicity.</p><p></p><p class="headingAnchor" id="H2483647"><span class="h4">Gemcitabine</span><span class="headingEndMark"> — </span>Limited data suggest that <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> may be a reasonable substitute for patients who are unable to receive <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> for whatever reason. In a series of nine patients with an obstructive uropathy, chemoradiation was administered with weekly gemcitabine (300 mg/m<sup>2</sup>); four patients underwent a percutaneous nephrostomy placement prior to chemoradiation [<a href="#rid22">22</a>]. All patients were able to complete treatment, although toxicities were common, including grade 3 neutropenia, dermatitis, proctitis, and colitis. Following treatment, all patients normalized their creatinine. With a median follow-up of 11 months, all patients were alive; two had evidence of recurrent disease.</p><p>Beyond these considerations, the limited data suggest that other agents commonly used in cervical cancer should <strong>not</strong> be administered as a component of primary chemoradiation. This includes:</p><p class="bulletIndent1"><span class="glyph">●</span>FU: Single-agent FU should not be used in this setting; one randomized trial showed that chemoradiation with this agent was no better than RT alone [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a>: Concurrent weekly paclitaxel plus RT has only been evaluated in one trial, which enrolled women with either locally advanced or recurrent cervical cancer [<a href="#rid24">24</a>]. Of 13 women with locally advanced disease, eight (62 percent) had a complete response. However, five (26 percent) experienced grade 3 small bowel toxicity, raising questions about whether treatment is feasible.</p><p></p><p class="headingAnchor" id="H10523862"><span class="h2">Radiation therapy</span><span class="headingEndMark"> — </span>For most women, RT (in conjunction with chemotherapy) is delivered to the pelvis using external beam RT (EBRT). Cervical brachytherapy is also administered in an effort to maximize local control. Two issues that arise in the design of the RT field are the treatment of the para-aortic nodal region and timing of RT treatment. These are discussed below.</p><p class="headingAnchor" id="H1286394"><span class="h3">Role of brachytherapy</span><span class="headingEndMark"> — </span>Brachytherapy is the local application of radiation to the cervix/vagina. It is an essential component of treatment for locally advanced cervical cancer and allows for a higher dose of RT to the cervix while sparing the surrounding normal tissue.</p><p class="headingAnchor" id="H1917207402"><span class="h4">Rationale</span><span class="headingEndMark"> — </span>The importance of brachytherapy was shown in a 2013 study that included over 7000 women with stage IB2 to IVA cervical cancer identified from the Surveillance, Epidemiology, and End Results (SEER) database [<a href="#rid25">25</a>]. Using a matched cohort analysis of patients treated between 2000 and 2009, the use of brachytherapy resulted in significantly higher rates of cancer-specific survival (64 versus 52 percent) and OS (58 versus 46 percent) at four years. Unfortunately, this study also reported a decreased utilization rate of brachytherapy between 1998 and 2009 from 83 to 58 percent, respectively. This decrease in use was seen regardless of stage and histologic type.</p><p>A second population-based study from the National Cancer Database analyzed data for 7654 patients treated between January 2004 and December 2011 with stages IIB to IVA cervical carcinoma. This study noted a decrease in use of brachytherapy for the curative treatment of cervical cancer from 97 percent in 2004 to 86 percent in 2011. The authors also reported that in the same time period, use of advanced technologies such as intensity-modulated RT (IMRT) or stereotactic body RT (SBRT) for a boost increased from 3.3 to 14 percent. In a multivariable survival analysis, using IMRT or SBRT for a boost resulted in inferior OS compared with brachytherapy (HR 1.86). This decrease in survival had a higher HR than the survival decrease when chemotherapy was not given (HR 1.56) [<a href="#rid26">26</a>]. In a Quality Research in Radiation Oncology study, the percentage of patients not receiving brachytherapy increased from 6 percent in a 1996 to 1999 survey to 13 percent in a 2005 to 2007 survey. In addition, 65 percent of patients receiving a boost were treated in a facility that treated fewer than three intact cervical cancer patients per year [<a href="#rid27">27,28</a>]. These data highlight the importance of brachytherapy in the treatment of cervical cancer. Given the data demonstrating underutilization, we recommend that these patients be treated at centers where the expertise to perform brachytherapy is available.</p><p class="headingAnchor" id="H2368411943"><span class="h4">Timing and technique</span><span class="headingEndMark"> — </span>Brachytherapy is initiated during EBRT once optimal tumor reduction is achieved. Adequate cervical regression typically occurs between two and five weeks of therapy depending on presenting tumor stage and size and response to therapy. It can be delivered with either a low-dose rate (LDR), pulse-dose rate (PDR), or high-dose rate (HDR) system. The International Commission on Radiation Units defines LDR brachytherapy as 0.4 to 2 Gy per hour; PDR brachytherapy delivers doses using the HDR source but treating only 10 to 30 minutes at a time, whereas HDR brachytherapy is delivered at &gt;12 Gy per hour. HDR and LDR appear to have similar efficacy and late complications in the management of cervical carcinoma, as suggested by retrospective single-institution reports, randomized trials, and a meta-analysis [<a href="#rid29">29-35</a>]. LDR brachytherapy requires one or two insertions and can begin near or after the completion of EBRT. The number of HDR insertions is variable across institutions, but most commonly is given as three to six insertions. The dose delivered per brachytherapy procedure is adjusted to account for the total number of insertions.</p><p>EBRT is delivered once daily for 25 days for a total dose of 45 Gy, usually with 3D conformal therapy. If there is gross nodal disease, a boost to the nodes should be considered interdigitated with the brachytherapy. There is evidence that IMRT can deliver the nodal boost simultaneous to the external beam and better spare normal tissues, but randomized data evaluating the efficacy are pending  (<a class="graphic graphic_diagnosticimage graphicRef114744" href="/d/graphic/114744.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef114743" href="/d/graphic/114743.html" rel="external">image 2</a>).</p><p>Three techniques can be employed:</p><p class="bulletIndent1"><span class="glyph">●</span>Intracavitary brachytherapy – With intracavitary brachytherapy, a variety of applicators can be employed. These include the placement of an intrauterine tandem with vaginal ovoids, vaginal cylinders, or a vaginal ring  (<a class="graphic graphic_picture graphicRef51083" href="/d/graphic/51083.html" rel="external">picture 1</a>). The addition of the ovoids or ring to the tandem applicator provides a dose distribution that encompasses the at-risk paracervical tissues while providing a lower-dose distribution to the bladder and rectum. In addition, dose to the bladder and rectum can be reduced further with the use of shielded ovoids and vigorous packing. The choice of applicator is governed by clinician preference and comfort level, as well as patient anatomical considerations. We prefer ovoids, when possible, due to improved dosimetry and dosing to the vaginal fornices and parametria. Vaginal cylinders are employed when distal vaginal disease is present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial brachytherapy – With interstitial brachytherapy, needles are placed with a variety of freehanded and template-based techniques, at times with laparoscopic guidance  (<a class="graphic graphic_picture graphicRef79505" href="/d/graphic/79505.html" rel="external">picture 2</a>). The most common presentation necessitating the use of interstitial therapy is extensive vaginal involvement. The use of the hybrid approach with a tandem and ring or ovoids with a limited number of needles has been shown to increase the dose to the target and decrease the dose to the organs at risk [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PDR brachytherapy – PDR brachytherapy uses a single Iridium-192 source that is programmed to move through various dwell positions in placed applicators using remote afterloading technology. The movement of the source through the positions constitutes a single pulse, and the dose delivered per pulse; the time interval between pulses and the total pulse duration can be varied. PDR brachytherapy delivers a treatment in which the goal is to draw from the advantages of both HDR brachytherapy and traditional LDR brachytherapy.</p><p></p><p>Applicator placement typically requires intravenous conscious sedation or general anesthesia for patient comfort. Once the applicators are in place, treatments were traditionally planned using orthogonal radiographs to define prescription and normal tissue points of interest, but this is changing to image-guided brachytherapy using modern imaging such as computed tomography (CT) and magnetic resonance imaging (MRI)  (<a class="graphic graphic_diagnosticimage graphicRef51717" href="/d/graphic/51717.html" rel="external">image 3</a>).</p><p class="headingAnchor" id="H2679532799"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>In the most common brachytherapy planning methodology, the total dose is prescribed to point A, which represents the paracervical tissues  (<a class="graphic graphic_figure graphicRef66135" href="/d/graphic/66135.html" rel="external">figure 1</a>). The prescribed brachytherapy dose depends on tumor stage, initial disease bulk and response to pelvic RT, ability to displace bladder and rectum, and use of LDR, HDR, or PDR technique. The total prescription dose to point A is 80 to 90 Gy LDR equivalent, depending on tumor stage [<a href="#rid37">37,38</a>]. A biologically effective dose is calculated and used when comparing HDR and LDR brachytherapy. The choice of dose for HDR also depends upon the number of fractions, for which there are multiple accepted regimens [<a href="#rid38">38</a>]. We prescribe a total brachytherapy dose of 27.5 Gy in five fractions when given with concurrent chemotherapy, or with a good response to external therapy; or 30 Gy in five fractions with RT alone, or with a poor response to chemotherapy. Another commonly used regimen is four fractions of 7 Gy.</p><p class="headingAnchor" id="H2066445752"><span class="h4">Image-guided adaptive brachytherapy</span><span class="headingEndMark"> — </span>Three-dimensional techniques with CT- or MRI-based brachytherapy planning is used in some institutions to escalate the dose to the target while accurately assessing the dose delivered to surrounding tissue at risk for toxicity. The use of this technique, called image-guided adaptive brachytherapy (IGABT), is increasing as experience and data regarding its efficacy become available [<a href="#rid39">39-43</a>].</p><p>As an example, in a prospective cohort study, among 1341 patients with locally advanced cervical cancer, MRI-based IGABT was associated with a five-year local control rate of 92 percent; five-year incidence of grade ≥3 morbidity was 6.8 percent for genitourinary events, 8.5 percent for gastrointestinal events, 5.7 percent for vaginal events, and 3.2 percent for fistulae [<a href="#rid44">44,45</a>].</p><p>Data suggest improvements in toxicity with IGABT relative to conventional techniques. In a randomized trial including 300 patients with cervical cancer receiving adjuvant pelvic radiation and vaginal brachytherapy, the three-year cumulative incidence of grade ≥2 gastrointestinal toxicity was 21 percent with image-guided brachytherapy versus 42 percent with conventional brachytherapy (HR 0.46, 95% CI 0.29-0.73) [<a href="#rid46">46</a>]. The incidence of grade ≥2 any late toxicity was 28 versus 49 percent, respectively (HR 0.50, 95% CI 0.33-0.76). The three-year DFS rates in the image-guided intensity-modulated RT versus the three-dimensional conformal RT arm were 77 versus 81 percent (HR 1.03, 95% CI 0.62-1.71, respectively).</p><p>Observational studies have similarly suggested improvements with IGABT over conventional brachytherapy in regards to toxicity, without compromising disease outcomes [<a href="#rid42">42,47-50</a>]. One prospective study including over 200 patients with advanced cervical cancer treated with chemoradiation followed by either IGABT or conventional brachytherapy found that IGABT was associated with an improvement in two-year locoregional control rate (70 versus 61 percent) and a reduction of grade 3 to 4 morbidity (1 versus 14 percent) when compared with conventional brachytherapy [<a href="#rid47">47</a>]. A nonsignificant trend towards improved survival was also observed (74 versus 65 percent, respectively). Data from ongoing prospective studies will provide further insight to the relative benefits and risks associated with IGABT.</p><p class="headingAnchor" id="H30045461"><span class="h3">Treatment of para-aortic nodes</span><span class="headingEndMark"> — </span>Women with evidence of para-aortic node involvement have a poor prognosis with a five-year survival rate of approximately 40 percent [<a href="#rid51">51</a>]. Despite low-quality data, it is routine practice to treat these patients with extended field RT. This entails extending the superior pelvic field border to the level of the T12 to L1 disk space in order to include the para-aortic nodes  (<a class="graphic graphic_diagnosticimage graphicRef59921" href="/d/graphic/59921.html" rel="external">image 4</a>).</p><p>There are no trials that compare chemoradiation using extended field RT (to cover the para-aortic region) versus pelvic RT, but given their high risk of disease progression and death, we prefer to treat these women with extended field RT with concurrent <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>. However, it is critical that women be counseled that such treatment is associated with a high risk of serious acute and late toxicity [<a href="#rid52">52-55</a>]. Many centers have chosen to use IMRT, at least to the para-aortic nodal region, to decrease morbidity and allow dose escalation to the involved nodes.</p><p>In the largest study, the Gynecologic Oncology Group enrolled 95 women with histologically confirmed para-aortic node metastases and treated them with concomitant chemoradiation using extended field RT and reported the following results [<a href="#rid53">53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The three-year OS and PFS rates for the entire group were 39 and 34 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The rate of grade 3 or higher gastrointestinal toxicity was 19 percent, likely due to a lower dose to the para-aortic region used in this study compared with the Radiation Therapy Oncology Group (RTOG) study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The rate of late morbidity at four years was 14 percent.</p><p></p><p>These data suggest that disease control can be attained in some women with locally advanced cervical cancer. However, treatment is associated with a high rate of acute and late toxicity.</p><p>In another small, single-institution, prospective study, the treatment of para-aortic node metastases with IMRT was compared with conventional para-aortic field RT [<a href="#rid56">56</a>]. Compared with conventional RT, IMRT resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>Significantly higher rates of tumor response and OS at two and three years</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less hematologic and gastrointestinal toxicity, although a higher dose was delivered with IMRT to the nodes.</p><p></p><p>Given the lack of data that prophylactically extending the RT field in women without para-aortic node involvement improves outcomes, the acute and late toxicity risks of extended-field RT must be taken into consideration. Therefore, we suggest not administering full extended-field RT for women without evidence of para-aortic node involvement, although extension of the upper border of the field by 5 cm above the last gross nodal disease (or to the level of the renal vessels) detected is often advised.</p><p class="headingAnchor" id="H4"><span class="h3">Importance of time to completion of chemoradiation</span><span class="headingEndMark"> — </span>For all women undergoing chemoradiation, treatment should be completed within eight weeks. Although older studies demonstrated the importance of the timely completion of RT [<a href="#rid57">57-59</a>], there are limited data on the importance of time to completion for women undergoing chemoradiation, but the preponderance of data would suggest that even with chemoradiation, treatment should be competed in seven to nine weeks. [<a href="#rid59">59-61</a>].</p><p>In one series of 113 women with stage IB to IIIB disease, with a median follow-up of 26 months, time to completion of brachytherapy &gt;56 days was associated with a higher rate of disease progression within the pelvis (26 versus 9 percent; HR 2.8, 95% CI 1.2-16) [<a href="#rid60">60</a>]. However, the time to completion of chemoradiation was not a significant factor for distant disease progression or disease-specific mortality. Two other studies at this time demonstrated that prolongation of treatment beyond seven weeks resulted in decreased pelvic control rates of 0.7 to 0.85 percent per day of prolongation and an 0.6-percent reduction in survival [<a href="#rid57">57,62</a>].</p><p>Another study of 480 women evaluating treatment duration with and without chemotherapy suggested that with RT alone, treatment duration greater than or equal to 62 days may impact DFS [<a href="#rid63">63</a>]. When chemoradiation therapy was administered, treatment duration did not predict for in-field relapse, DFS, or OS. A subsequent review of this issue evaluated patients with advanced cervical cancer treated between 2003 and 2011, and 95 percent were treated with concurrent chemoradiation [<a href="#rid64">64</a>]. Prolonged duration of treatment (&gt;10 to 12 weeks) was associated with worsened DFS and OS.</p><p class="headingAnchor" id="H10523258"><span class="h2">Role of hysterectomy after chemoradiation</span><span class="headingEndMark"> — </span>Some surgeons perform a simple extrafascial hysterectomy following chemoradiation in select patients with disease characteristics that suggest a higher risk of relapse (eg, initially large cervical lesion &gt;7 cm, lower uterine segment involvement, or those with post-treatment residual disease). However, there is no evidence that doing so improves survival outcomes in this population, and most centers do <strong>not</strong> routinely perform hysterectomy following chemoradiation.</p><p>There are few high-quality data regarding this issue [<a href="#rid65">65-67</a>]. In a randomized trial including 61 patients with stage IB2 to II cervical cancer who had a complete clinical and radiologic response after primary treatment with chemoradiation, those assigned to hysterectomy compared with no hysterectomy had similar event-free survival and OS at three-year follow-up [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H620051171"><span class="h2">No role for systemic chemotherapy after chemoradiation</span><span class="headingEndMark"> — </span>We suggest not administering systemic chemotherapy for women completing primary chemoradiation, as there is limited evidence of benefit to justify the additional toxicity risks.</p><p>In a randomized trial including 919 patients with locally advanced cervical cancer, those assigned to standard cisplatin-based chemoradiation followed by four cycles of adjuvant <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> experienced similar OS at five years as those assigned to concurrent chemoradiation only (72 versus 71 percent; HR 0.90, 95% CI 0.70-1.17) [<a href="#rid68">68</a>]. PFS at five years was also similar between the groups (63 versus 62 percent; HR 0.86, 95% CI 0.69-1.08). Grade ≥3 adverse events within a year of randomization occurred in 81 versus 62 percent, respectively.</p><p>By contrast, in an earlier trial, women who received two cycles of systemic intravenous <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> after chemoradiation had significant improvements in both PFS and OS compared with women who received cisplatin-alone-based chemoradiation and no further chemotherapy [<a href="#rid16">16</a>]. However, as discussed above, it is not clear if the survival benefit was due to combination chemotherapy delivered with RT, following RT, or both. In addition, the Gynecologic Oncology Group ran a similar trial of gemcitabine followed by cisplatin with concomitant RT, but this trial was stopped due to excessive grade 3/4 toxicities [<a href="#rid69">69</a>].</p><p>Given the concerns for toxicity and the unclear contribution of systemic treatment, we do not administer further treatment after chemoradiation.</p><p class="headingAnchor" id="H10523617"><span class="h1">NEOADJUVANT CHEMOTHERAPY</span><span class="headingEndMark"> — </span>Neoadjuvant chemotherapy prior to definitive hysterectomy does not offer an overall survival (OS) advantage relative to primary chemoradiation, and in randomized trials discussed below, it has been associated with inferior disease-free survival (DFS). Therefore, in geographic areas where chemoradiation can be performed, we prefer to administer chemoradiation rather than neoadjuvant chemotherapy for locally advanced cervical cancer. However in parts of Europe, Asia, and South America where access to radiotherapy facilities is limited, neoadjuvant chemotherapy before surgery is an appropriate option for women with locally advanced disease.</p><p>In a phase III trial, 633 women with stage IB2, IIA, or IIB squamous cervical cancer were randomly assigned to either three cycles of neoadjuvant chemotherapy (<a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> once every three weeks) followed by radical hysterectomy or to standard chemoradiation. Compared with standard chemoradiation, those receiving neoadjuvant chemotherapy followed by surgery experienced worse five-year DFS (69.3 versus 76.7 percent, respectively; hazard ratio [HR] 1.38, 95% CI 1.02-1.87) [<a href="#rid70">70</a>]. However, five-year OS was similar between the two groups (75.4 versus 74.7 percent, respectively; HR 1.025, 95% CI 0.75-1.40). Delayed toxicities at two years or later after treatment completion were worse in the group treated with chemoradiation compared with neoadjuvant chemotherapy, and included rectal (3.5 versus 2.2 percent, respectively), bladder (3.5 versus 1.6 percent), and vaginal (25.6 versus 12.0 percent) complications.</p><p>In preliminary results of a separate phase III trial (European Organisation for Research and Treatment of Cancer [EORTC] 55994), among 620 patients with stage IB2 to IIB cervical cancer, those randomly assigned to neoadjuvant chemotherapy followed by surgery experienced worsened five-year progression-free survival rates (57 versus 66 percent; difference 9 percent, 95% CI 2 to 18 percent) and comparable five-year OS rates (72 versus 76 percent; HR 0.87, 95% CI 0.65-0.15) as those receiving concomitant chemoradiation [<a href="#rid71">71</a>]. While short-term grade ≥3 toxicities were higher with neoadjuvant therapy followed by surgery (41 and 23 percent, respectively), long-term toxicities were less frequent compared with chemoradiation (15 versus 21 percent).</p><p class="headingAnchor" id="H23"><span class="h1">POST-TREATMENT IMAGING AND SURVEILLANCE</span><span class="headingEndMark"> — </span>We obtain positron emission tomography (PET)/computed tomography (CT) three to four months following therapy for its prognostic value. The main goal of subsequent post-treatment surveillance is early detection of those recurrences that might be amenable to potentially curative therapy. The optimal surveillance strategy has not been established. Consensus-based guidelines for post-treatment surveillance are discussed separately. (See  <a class="medical medical_review" href="/d/html/3227.html" rel="external">"Invasive cervical cancer: Patterns of recurrence and post-treatment surveillance", section on 'Surveillance strategies'</a>.)</p><p>In a study of 238 patients with cervical cancer treated with chemoradiation, all patients had a pretreatment fluorodeoxyglucose positron emission tomography (FDG-PET) and a post-therapy FDG-PET 8 to 16 weeks after treatment completion. Among these patients, 38 percent experienced a recurrence [<a href="#rid72">72</a>]. The rate of recurrence among those with complete metabolic response, partial metabolic response (PMR), and progressive disease was 23, 65, and 100 percent, respectively, differences that were statistically significant. While most failures were distant, a PMR predicted for locoregional failure. Of those recurring after a PMR on post-treatment PET, 42 percent had a component of distant disease versus 96 percent among those with progressive disease.</p><p class="headingAnchor" id="H620051306"><span class="h1">QUALITY OF LIFE CONSIDERATIONS</span><span class="headingEndMark"> — </span>Cervical cancer treatment may have a negative impact on quality of life, which can persist for years following treatment, particularly among women who were previously treated with radiation therapy [<a href="#rid73">73-75</a>]. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Long-term quality of life'</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The major prognostic factors affecting survival are stage, nodal status, tumor volume, depth of cervical stromal invasion, lymphovascular space invasion (LVSI), and to a lesser extent, histologic type and grade. A summary of survival rates by stage of disease according to the latest International Federation of Gynecology and Obstetrics (FIGO) data is available  (<a class="graphic graphic_table graphicRef64747" href="/d/graphic/64747.html" rel="external">table 3</a>) [<a href="#rid76">76</a>].</p><p>Women with locally advanced cervical cancer have a higher rate of recurrence and worse survival than those with early-stage disease. After surgery alone, the rate of relapse is at least 30 percent [<a href="#rid1">1,2</a>]. According to statistics from the American Cancer Society, the five-year survival rate by stage is [<a href="#rid77">77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IB – 80 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IIA – 63 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IIB – 58 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage III – 30 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IVA – 16 percent</p><p></p><p>Human papillomavirus status may also affect prognosis. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H6927280"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H6927288"><span class="h2">Incidentally diagnosed cancer</span><span class="headingEndMark"> — </span>In rare instances, women who undergo a simple hysterectomy for what was thought to be cervical intraepithelial neoplasia (or for another benign indication) have a final pathology result showing cervical cancer. For women in this situation, we suggest a radical parametrectomy and upper vaginectomy with lymph node evaluation or chemoradiation. Single-institutional studies have shown that radical parametrectomy is feasible and results in recurrence rates between 0 to 11 percent and a five-year overall survival rate over 96 percent [<a href="#rid78">78-80</a>].</p><p>Adjuvant chemoradiation may be a reasonable alternative to further surgery for women who are not candidates for radical pelvic surgery or those with disease that cannot be easily encompassed by a radical parametrectomy. However, a retrospective study involving 147 patients with occult invasive cervical cancer suggests patients treated with this approach have a higher rate of recurrence compared with those treated with radical parametrectomy (7 versus 0 percent) [<a href="#rid79">79</a>]. In addition, chemoradiation resulted in a 27 percent rate of late complications related to radiation therapy (RT). (See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H620052119"><span class="h2">Women who are poor candidates for primary chemoradiation</span><span class="headingEndMark"> — </span>We perform a primary modified radical hysterectomy in select patients with stage I disease (&lt;4 cm tumor) who are not candidates for chemoradiation. This includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Women with acute or chronic pelvic inflammatory disease in whom chemotherapy is a relative contraindication (see  <a class="medical medical_review" href="/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with a coexistent pelvic mass that is suggestive of a dual malignancy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women with anatomic alterations that make optimal RT difficult</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women in whom compliance with RT would be difficult</p><p></p><p>In one study, these criteria were used to select 95 women with stage IB cervical cancer for primary surgery [<a href="#rid81">81</a>]. The five-year survival rate in this highly selected group was 91 percent.</p><p>For women who are not surgical candidates, we suggest primary RT alone.</p><p class="headingAnchor" id="H57371144"><span class="h2">Considerations during the COVID-19 pandemic</span><span class="headingEndMark"> — </span>The COVID-19 pandemic has increased the complexity of cancer care. Important issues in areas where viral transmission rates are high include balancing the risk from treatment delay versus harm from COVID-19, ways to minimize negative impacts of social distancing during care delivery, and appropriately and fairly allocating limited health care resources. These and other recommendations for cancer care during active phases of the COVID-19 pandemic are discussed separately. (See  <a class="medical medical_review" href="/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.)</p><p class="headingAnchor" id="H2854754966"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113940.html" rel="external">"Society guideline links: Treatment of cervical cancer"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/859.html" rel="external">"Patient education: Cervical cancer treatment; early-stage cancer (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/868.html" rel="external">"Patient education: Fertility preservation in early-stage cervical cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of locally advanced-stage cervical cancer</strong> – Locally advanced cervical cancer is defined as: disease confined to the cervix with a clinically visible tumor &gt;4 cm (stage IB3); disease that invades beyond the uterus, but involves less than the upper two-thirds of the vagina (stage II); disease that extends to the pelvic sidewall, involves the lower third of vagina, and/or causes hydronephrosis or nonfunctioning kidney (stage III); or disease that extends to the rectum or bladder, or beyond the true pelvis (stage IVA  (<a class="graphic graphic_table graphicRef119447" href="/d/graphic/119447.html" rel="external">table 1</a>)). (See <a class="local">'Definition of locally advanced-stage cervical cancer'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary chemoradiation</strong> – For women with locally advanced cervical cancer, we suggest primary chemoradiation rather than primary surgery, neoadjuvant chemotherapy followed by surgery, or radiation therapy (RT) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We acknowledge that there are greater benefits to treatment for women with earlier-stage (stage IB to IIB) rather than later-stage (stage III to IVA) disease. We suggest weekly <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> during RT rather than combination chemotherapy (eg, cisplatin plus <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>) during RT (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Primary chemoradiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> – We perform a positron emission tomography (PET)/computed tomography (CT) in all patients with locally advanced cervical cancer in order to define the extent of disease and evaluate the pelvic and para-aortic lymph nodes. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to para-aortic nodes</strong> – For women with a positive PET/CT scan showing para-aortic node involvement, some experts perform a lymphadenectomy or CT-guided biopsy for pathologic confirmation. Other experts do not perform further evaluation if the PET/CT scan is positive. (See <a class="local">'Pretreatment evaluation'</a> above and <a class="local">'Treatment of para-aortic nodes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For women with suspected or pathologically confirmed para-aortic node involvement, we suggest primary chemoradiation with extended-field RT (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, consideration of the risks of treatment should be discussed with patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest not administering full extended-field RT for women without known or suspected para-aortic node involvement (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of hysterectomy after chemoradiation</strong> – We suggest not performing a post-treatment hysterectomy following primary chemoradiation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, some experts offer patients with an initially large cervical lesion (&gt;7 cm), lower uterine segment involvement, or a high post-treatment residual tumor volume a simple hysterectomy at the completion of treatment. (See <a class="local">'Role of hysterectomy after chemoradiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-treatment surveillance</strong> – Following primary treatment with curative intent, patients are monitored serially with history and physical examination and Pap smears. For prognostic purposes, we obtain a PET/CT three to four months following completion of therapy. We reserve subsequent surveillance imaging only if a recurrence is suspected. (See <a class="local">'Post-treatment imaging and surveillance'</a> above.)</p><p></p><p class="headingAnchor" id="H21436063"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jennifer F De Los Santos, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006; 65:169.</a></li><li><a class="nounderline abstract_t">Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 38:352.</a></li><li><a class="nounderline abstract_t">Olawaiye AB, Baker TP, Washington MK, Mutch DG. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J Clin 2021; 71:287.</a></li><li><a class="nounderline abstract_t">Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 2019; 145:129.</a></li><li><a class="nounderline abstract_t">Corrigendum to "Revised FIGO staging for carcinoma of the cervix uteri" [Int J Gynecol Obstet 145(2019) 129-135]. Int J Gynaecol Obstet 2019; 147:279.</a></li><li><a class="nounderline abstract_t">Rose PG, Ali S, Whitney CW, et al. Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 117:270.</a></li><li><a class="nounderline abstract_t">Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17:64.</a></li><li><a class="nounderline abstract_t">Yessaian A, Magistris A, Burger RA, Monk BJ. Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecol Oncol 2004; 94:61.</a></li><li><a class="nounderline abstract_t">Yamashita H, Okuma K, Kawana K, et al. Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study. Am J Clin Oncol 2010; 33:583.</a></li><li><a class="nounderline abstract_t">Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18:1606.</a></li><li><a class="nounderline abstract_t">Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010; :CD008285.</a></li><li><a class="nounderline abstract_t">Shrivastava S, Mahantshetty U, Engineer R, et al. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial. JAMA Oncol 2018; 4:506.</a></li><li><a class="nounderline abstract_t">Fachini AMD, Zuliani AC, Sarian LO, et al. Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial. Gynecol Oncol 2021; 160:379.</a></li><li><a class="nounderline abstract_t">Kim YS, Shin SS, Nam JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol 2008; 108:195.</a></li><li><a class="nounderline abstract_t">Ang KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol 2004; 22:4657.</a></li><li><a class="nounderline abstract_t">Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011; 29:1678.</a></li><li><a class="nounderline abstract_t">Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9:13.</a></li><li><a class="nounderline abstract_t">Cetina L, Garcia-Arias A, Uribe Mde J, et al. Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer. Eur J Gynaecol Oncol 2008; 29:608.</a></li><li><a class="nounderline abstract_t">Dubay RA, Rose PG, O'Malley DM, et al. Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol 2004; 94:121.</a></li><li><a class="nounderline abstract_t">Katanyoo K, Tangjitgamol S, Chongthanakorn M, et al. Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients. Gynecol Oncol 2011; 123:571.</a></li><li><a class="nounderline abstract_t">Nam EJ, Lee M, Yim GW, et al. Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks. Oncologist 2013; 18:843.</a></li><li><a class="nounderline abstract_t">Cetina L, Rivera L, Candelaria M, et al. Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. Anticancer Drugs 2004; 15:761.</a></li><li><a class="nounderline abstract_t">Thomas G, Dembo A, Ackerman I, et al. A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. Gynecol Oncol 1998; 69:137.</a></li><li><a class="nounderline abstract_t">Cerrotta A, Gardan G, Cavina R, et al. Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur J Gynaecol Oncol 2002; 23:115.</a></li><li><a class="nounderline abstract_t">Han K, Milosevic M, Fyles A, et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys 2013; 87:111.</a></li><li><a class="nounderline abstract_t">Gill BS, Lin JF, Krivak TC, et al. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. Int J Radiat Oncol Biol Phys 2014; 90:1083.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Moughan J, Erickson B, et al. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study. Int J Radiat Oncol Biol Phys 2004; 60:1144.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Ho A, Khalid N, et al. Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study. Int J Radiat Oncol Biol Phys 2014; 89:249.</a></li><li><a class="nounderline abstract_t">Petereit DG, Sarkaria JN, Potter DM, Schink JC. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience. Int J Radiat Oncol Biol Phys 1999; 45:1267.</a></li><li><a class="nounderline abstract_t">Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, et al. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys 2004; 59:1424.</a></li><li><a class="nounderline abstract_t">Hareyama M, Sakata K, Oouchi A, et al. High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Cancer 2002; 94:117.</a></li><li><a class="nounderline abstract_t">Falkenberg E, Kim RY, Meleth S, et al. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience. Brachytherapy 2006; 5:49.</a></li><li><a class="nounderline abstract_t">Parker K, Gallop-Evans E, Hanna L, Adams M. Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution. Int J Radiat Oncol Biol Phys 2009; 74:140.</a></li><li><a class="nounderline abstract_t">Hellebust TP, Kristensen GB, Olsen DR. Late effects after radiotherapy for locally advanced cervical cancer: comparison of two brachytherapy schedules and effect of dose delivered weekly. Int J Radiat Oncol Biol Phys 2010; 76:713.</a></li><li><a class="nounderline abstract_t">Liu R, Wang X, Tian JH, et al. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev 2014; :CD007563.</a></li><li><a class="nounderline abstract_t">Jastaniyah N, Yoshida K, Tanderup K, et al. A volumetric analysis of GTVD and CTVHR as defined by the GEC ESTRO recommendations in FIGO stage IIB and IIIB cervical cancer patients treated with IGABT in a prospective multicentric trial (EMBRACE). Radiother Oncol 2016; 120:404.</a></li><li><a class="nounderline abstract_t">Nag S, Chao C, Erickson B, et al. The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002; 52:33.</a></li><li><a class="nounderline abstract_t">Viswanathan AN, Beriwal S, De Los Santos JF, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 2012; 11:47.</a></li><li><a class="nounderline abstract_t">Zwahlen D, Jezioranski J, Chan P, et al. Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix. Int J Radiat Oncol Biol Phys 2009; 74:1157.</a></li><li><a class="nounderline abstract_t">Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006; 78:67.</a></li><li><a class="nounderline abstract_t">Haie-Meder C, Pötter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005; 74:235.</a></li><li><a class="nounderline abstract_t">Lin AJ, Kidd E, Dehdashti F, et al. Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. Int J Radiat Oncol Biol Phys 2019; 103:1088.</a></li><li><a class="nounderline abstract_t">Schmid MP, Lindegaard JC, Mahantshetty U, et al. Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study. J Clin Oncol 2023; 41:1933.</a></li><li><a class="nounderline abstract_t">Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 2021; 22:538.</a></li><li><a class="nounderline abstract_t">Kirchheiner K, Smet S, Jürgenliemk-Schulz IM, et al. Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study. Int J Radiat Oncol Biol Phys 2022; 112:400.</a></li><li><a class="nounderline abstract_t">Chopra S, Gupta S, Kannan S, et al. Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial. J Clin Oncol 2021; 39:3682.</a></li><li><a class="nounderline abstract_t">Charra-Brunaud C, Harter V, Delannes M, et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol 2012; 103:305.</a></li><li><a class="nounderline abstract_t">Pötter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 2007; 83:148.</a></li><li><a class="nounderline abstract_t">Castelnau-Marchand P, Chargari C, Maroun P, et al. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer. Gynecol Oncol 2015; 139:288.</a></li><li><a class="nounderline abstract_t">Lindegaard JC, Fokdal LU, Nielsen SK, et al. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol 2013; 52:1510.</a></li><li><a class="nounderline abstract_t">Macdonald OK, Chen J, Dodson M, et al. Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix. Am J Clin Oncol 2009; 32:411.</a></li><li><a class="nounderline abstract_t">Grigsby PW, Lu JD, Mutch DG, et al. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10. Int J Radiat Oncol Biol Phys 1998; 41:817.</a></li><li><a class="nounderline abstract_t">Varia MA, Bundy BN, Deppe G, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1998; 42:1015.</a></li><li><a class="nounderline abstract_t">Small W Jr, Winter K, Levenback C, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys 2007; 68:1081.</a></li><li><a class="nounderline abstract_t">Grigsby PW, Heydon K, Mutch DG, et al. Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2001; 51:982.</a></li><li><a class="nounderline abstract_t">Du XL, Sheng XG, Jiang T, et al. Intensity-modulated radiation therapy versus para-aortic field radiotherapy to treat para-aortic lymph node metastasis in cervical cancer: prospective study. Croat Med J 2010; 51:229.</a></li><li><a class="nounderline abstract_t">Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995; 32:1275.</a></li><li><a class="nounderline abstract_t">Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 1992; 25:273.</a></li><li><a class="nounderline abstract_t">Chen SW, Liang JA, Yang SN, et al. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. Radiother Oncol 2003; 67:69.</a></li><li><a class="nounderline abstract_t">Song S, Rudra S, Hasselle MD, et al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer 2013; 119:325.</a></li><li><a class="nounderline abstract_t">Nugent EK, Case AS, Hoff JT, et al. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol 2010; 116:438.</a></li><li><a class="nounderline abstract_t">Petereit DG, Sarkaria JN, Chappell R, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995; 32:1301.</a></li><li><a class="nounderline abstract_t">Shaverdian N, Gondi V, Sklenar KL, et al. Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 2013; 86:562.</a></li><li><a class="nounderline abstract_t">Tergas AI, Neugut AI, Chen L, et al. Radiation Duration in Women with Cervical Cancer Treated with Primary Chemoradiation: A Population-Based Analysis. Cancer Invest 2016; 34:137.</a></li><li><a class="nounderline abstract_t">Morice P, Rouanet P, Rey A, et al. Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer. Oncologist 2012; 17:64.</a></li><li><a class="nounderline abstract_t">Darus CJ, Callahan MB, Nguyen QN, et al. Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. Int J Gynecol Cancer 2008; 18:730.</a></li><li><a class="nounderline abstract_t">Kokka F, Bryant A, Olaitan A, et al. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev 2022; 8:CD010260.</a></li><li><a class="nounderline abstract_t">Mileshkin LR, Moore KN, Barnes EH, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol 2023; 24:468.</a></li><li><a class="nounderline abstract_t">Rose PG, Degeest K, McMeekin S, Fusco N. A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2007; 107:274.</a></li><li><a class="nounderline abstract_t">Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol 2018; 36:1548.</a></li><li><a class="nounderline abstract_t">Kenter G, Greggi S, Vergote I, et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994. J Clin Oncol 2019; 37S: ASCO #5503.</a></li><li><a class="nounderline abstract_t">Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2012; 83:185.</a></li><li><a class="nounderline abstract_t">Vistad I, Fosså SD, Dahl AA. A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol 2006; 102:563.</a></li><li><a class="nounderline abstract_t">Greimel ER, Winter R, Kapp KS, Haas J. Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology 2009; 18:476.</a></li><li><a class="nounderline abstract_t">Kirwan JM, Symonds P, Green JA, et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003; 68:217.</a></li><li><a class="nounderline abstract_t">Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S43.</a></li><li class="breakAll">Survival rates for cervical cancer. American Cancer Society. http://www.cancer.org/Cancer/CervicalCancer/DetailedGuide/cervical-cancer-survival (Accessed on June 25, 2012).</li><li><a class="nounderline abstract_t">Leath CA 3rd, Straughn JM, Bhoola SM, et al. The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy. Gynecol Oncol 2004; 92:215.</a></li><li><a class="nounderline abstract_t">Park JY, Kim DY, Kim JH, et al. Management of occult invasive cervical cancer found after simple hysterectomy. Ann Oncol 2010; 21:994.</a></li><li><a class="nounderline abstract_t">Li J, Xu H, Chen Y, et al. Laparoscopic nerve-sparing radical parametrectomy for occult early-stage invasive cervical cancer after simple hysterectomy. Int J Gynecol Cancer 2012; 22:1383.</a></li><li><a class="nounderline abstract_t">Allen HH, Nisker JA, Anderson RJ. Primary surgical treatment in one hundred ninety-five cases of stage IB carcinoma of the cervix. Am J Obstet Gynecol 1982; 143:581.</a></li></ol></div><div id="topicVersionRevision">Topic 3187 Version 72.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16427212" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2227547" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33784415" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30656645" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Revised FIGO staging for carcinoma of the cervix uteri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31571232" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Corrigendum to "Revised FIGO staging for carcinoma of the cervix uteri" [Int J Gynecol Obstet 145(2019) 129-135].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20181381" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30659131" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262120" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20065848" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764420" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091664" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29423520" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33341239" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17963825" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534361" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444871" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9541678" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Carboplatin versus cisplatin in solid tumors: an analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19115688" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Concurrent chemoradiation with carboplatin for elderly, diabetic and hypertensive patients with locally advanced cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262129" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21955483" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23821328" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494637" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chemoradiation with gemcitabine for cervical cancer in patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600821" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12013105" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849695" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Trends in the utilization of brachytherapy in cervical cancer in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25216857" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15519786" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24411621" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10613322" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15275728" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11815967" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16563997" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18922646" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19427739" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Late effects after radiotherapy for locally advanced cervical cancer: comparison of two brachytherapy schedules and effect of dose delivered weekly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25300170" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27452409" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A volumetric analysis of GTVD and CTVHR as defined by the GEC ESTRO recommendations in FIGO stage IIB and IIIB cervical cancer patients treated with IGABT in a prospective multicentric trial (EMBRACE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11777620" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22265437" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19101097" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403584" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15763303" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30445171" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36599120" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33794207" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34478833" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34506246" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22633469" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531904" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26364808" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23962242" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451800" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9652843" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869224" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17398031" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704321" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564766" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intensity-modulated radiation therapy versus para-aortic field radiotherapy to treat para-aortic lymph node metastasis in cervical cancer: prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635767" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1480773" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The effect of treatment duration in the local control of cervix cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12758242" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22806897" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19896180" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635769" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The adverse effect of treatment prolongation in cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23561652" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26986809" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Radiation Duration in Women with Cervical Cancer Treated with Primary Chemoradiation: A Population-Based Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22234626" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17949426" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35994243" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37080223" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17688925" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29432076" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22014958" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16716379" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18702067" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13129628" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161167" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161167" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14751161" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858083" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Management of occult invasive cervical cancer found after simple hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22964523" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Laparoscopic nerve-sparing radical parametrectomy for occult early-stage invasive cervical cancer after simple hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7091229" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Primary surgical treatment in one hundred ninety-five cases of stage IB carcinoma of the cervix.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
